Stoke Therapeutics, Inc. announced enrollment of the first patient in an observational study of children and adolescents ages 2 to 18 with Dravet syndrome. BUTTERFLY is a two-year observational study that is designed to evaluate seizure frequency and non-seizure comorbidities associated with the disease, including motor and speech impairment, intellectual and developmental disabilities, behavioral deficits and abnormal sleep patterns. Data from the study will support clinical development plans for the company’s lead therapeutic candidate, STK-001, an investigational new treatment for Dravet syndrome.
August 20, 2019
January 15, 2020
FANS Trial Testing Ketone Supplementation to Help Control Seizures in Children With Angelman Syndrome
A clinical trial is evaluating the safety and tolerability of a nutritional formulation containing the ketone beta-hydroxybutyrate (BHB) as a treatment to help control seizures in children with Angelman syndrome.